Three Middlemen Dominate U.S. Drug Market

Mark Cuban (on the Build or Break podcast) claims three pharmaceutical middlemen control roughly 85% of drug distribution, concentrating pricing power and insulating supply‑chain markup. If true, that concentration helps explain high retail drug prices and points to targeted antitrust or regulatory levers. — This frames drug‑price politics as a market‑structure problem that midterm‑level policymakers (state attorneys general, Congress) could act on, shifting debates from generic 'too expensive' complaints to concrete regulatory and antitrust responses.